EG432838 Inhibitors
EG432838 inhibitors are a class of chemical compounds specifically designed to inhibit the activity of the EG432838 enzyme or protein. These inhibitors exhibit a variety of structural features, depending on their mechanism of interaction with the enzyme. Generally, they consist of small organic molecules that can fit into the active or allosteric sites of the target protein, thereby modulating its activity. The structure-activity relationship (SAR) of these inhibitors is a key focus in their design, often involving modifications to their core chemical structure to optimize their binding affinity, specificity, and stability. These inhibitors typically contain functional groups like aromatic rings, heterocycles, and halogen substitutions, which contribute to their ability to form strong interactions with their protein target. For optimal inhibition, certain derivatives may be modified to enhance properties like solubility, permeability, and metabolic stability.
The mechanism of inhibition by EG432838 inhibitors can involve either competitive, non-competitive, or allosteric modes of action. Some inhibitors directly compete with the natural substrate for the enzyme's active site, while others bind to a distinct regulatory site, inducing conformational changes that decrease the enzyme's activity. Their biochemical properties often include selective binding to the enzyme, potentially through hydrogen bonding, hydrophobic interactions, and π-π stacking, which allows for tight binding to the target. The development and optimization of EG432838 inhibitors often require careful tuning of their chemical properties to enhance selectivity over similar enzymes and to achieve the desired potency. Furthermore, these inhibitors can be studied in various assays to assess their kinetic parameters, binding affinity, and selectivity profile, providing insights into their potential as research tools for understanding the biological pathways in which EG432838 is involved.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine inhibits Akt, a downstream component of transmembrane signaling. By targeting this pathway, it disrupts Gm5460's predicted transmembrane signaling receptor activity and potential involvement in toxin transport. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits PI3K, impacting the Akt pathway. Through this inhibition, Gm5460's involvement in transmembrane signaling receptor activity may be disrupted, affecting its potential role in toxin transport. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK, a kinase in the MAPK pathway. Gm5460's function may be indirectly affected as this inhibition alters the pathway, potentially influencing transmembrane signaling receptor activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, disrupting the Akt pathway. This disruption may indirectly inhibit Gm5460, impacting its predicted transmembrane signaling receptor activity and potential involvement in toxin transport. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK in the MAPK pathway. Gm5460 may be indirectly affected through disruption of the pathway, potentially influencing transmembrane signaling receptor activity and its role in toxin transport. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, affecting the Akt pathway. This inhibition may indirectly impact Gm5460 by disrupting the pathway, potentially influencing its predicted transmembrane signaling receptor activity and toxin transport role. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, a component of the MAPK pathway. Gm5460's function may be indirectly affected, as disruption of the pathway could influence its predicted transmembrane signaling receptor activity and potential toxin transport role. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
A769662 activates AMPK, affecting the Akt pathway. This activation may indirectly inhibit Gm5460 by influencing the pathway, potentially disrupting its predicted transmembrane signaling receptor activity and toxin transport role. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $175.00 $700.00 | 9 | |
PF-4708671 inhibits AMPK, impacting the Akt pathway. Gm5460 may be indirectly inhibited as this inhibition influences the pathway, potentially disrupting its predicted transmembrane signaling receptor activity and toxin transport role. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB, a component of various pathways. Gm5460 may be indirectly affected, as inhibition of NF-κB could influence its predicted transmembrane signaling receptor activity and potential role in toxin transport. | ||||||